# RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)

> **NCT00443846** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 247 (actual)

## Conditions studied

- Meningitis, Meningococcal
- Rotavirus Infections

## Interventions

- **BIOLOGICAL:** RotaTeq®
- **BIOLOGICAL:** NeisVac-C®

## Key facts

- **NCT ID:** NCT00443846
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02-13
- **Primary completion:** 2007-09-04
- **Final completion:** 2007-10-23
- **Target enrollment:** 247 (ACTUAL)
- **Last updated:** 2018-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00443846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00443846, "RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00443846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*